Loading...
Keywords
Last Name
Institution

Alan S. Gamis, MD, MPH

TitleChief, Section of Oncology
InstitutionChildren's Mercy Kansas City
DepartmentPediatrics
Address2401 Gillham Rd
Kansas City MO 64108
ORCID ORCID Icon0000-0003-1513-2893 Additional info
vCardDownload vCard
    Other Positions
    TitleAssociate Division Director, Hem/Onc/BMT
    InstitutionChildren's Mercy Kansas City
    DepartmentPediatrics

    TitleProfessor of Pediatrics
    InstitutionUniversity of Missouri-Kansas City
    DepartmentPediatrics

    TitleClinical Professor of Pediatrics
    InstitutionUniversity of Kansas Medical Center
    DepartmentPediatrics


    Collapse Biography 
    Collapse education and training
    University of Illinois, Chicago, ILMD1984
    University of Minnesota, Minneapolis, MNMPH1991
    University of Minnesota, Minneapolis, MN FellowshipPediatric Hematology/Oncology
    Children's Mercy Hospitals and Clinics, Kansas City, MOResidencyPediatrics

    Collapse Overview 

    Collapse Research 
    Collapse research overview
    Dr. Gamis' research expertise is in the design and development of multi-institutional clinical trials in childhood cancer, specifically in AML. He is a board certified Pediatric Hematologist/Oncologist and continues to care for patients with cancer in a large children's cancer center. He also trained as an Epidemiologist receiving an MPH in 1991 as a foundation for clinical trial development. He has been active in AML research activities in the Children's Oncology Group since 1993, first serving on several COG clinical trial committees (AML, Neuroblastoma, Hodgkin’s, Stem Cell Transplant, Epidemiology, & Supportive Care/Nursing), then chairing two large clinical trials. The first was the first phase III trial specifically for children with AML and Down Syndrome, COG A2971 - Treatment of Children with Down’s Syndrome and AML, MDS, and Transient Myeloproliferative Disorder, from 1996-2004.This was followed by a second national Phase III trial, COG-AAML0531- Phase III Randomized Trial of Gemtuzumab Combined with Conventional Chemotherapy for de novo Acute Myeloid Leukemia in Children, from 2004 until the 2010 and which led to the FDA approval of this agent in children. Dr. Gamis has served as a member of the COG Myeloid Scientific Disease Committee since 1996 and served as Chair of the committee from 2007-2013 overseeing all aspects of Myeloid Leukemia research (design, implementation, analysis, and strategic planning) during which time there was designed and developed numerous clinical trials in childhood AML. He has also served on the COG Epidemiology Steering Committee from 1992-1995 and the COG Stem Cell Transplant Steering Committee from 2002 to 2010. He was a founding member of the Pediatric Blood and Marrow Transplant Consortium (PBMTC) (now known as Pediatric Transplantation & Cellular Therapy Consortium (PTCTC)) beginning in 1992 ultimately serving as its Chair from 1999-2004 during which time he led the successful attainment of the UO1 NHLBI grant as an original clinical core center PI of the Bone Marrow Transplant Clinical Trials Network (BMT CTN). During this time he successfully joined the PBMTC with the COG through the NIH grant BAA-RM-04-23 grant, Re-engineering the Clinical Research Enterprise: Feasibility of Integrating and Expanding Clinical Research Networks, from 2004-2008. Since 2016, Dr Gamis has served on the NCI PDQ Pediatric Editorial Board overseeing the AML & Myeloid Disorders summary.

    Locally, he was the Director of the Children's Mercy Cancer Center from 1999-2023, and oversaw all clinical and research activities related to cancer care and successfully oversaw the program's expansion, program development and ultimately consortium institutional partnership with the NCI-designated University of Kansas Cancer Center. Since 2021, Dr Gamis has served as the Interim Division Director of the Division of Hematology/Oncology/Bone Marrow Transplantation.

    Collapse Bibliography 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. H Elsayed A, Cao X, Marrero RJ, Nguyen NHK, Wu H, Ni Y, Ribeiro RC, Tobias H, Valk PJ, B?liveau F, Richard-Carpentier G, H?bert J, Zwaan CM, Gamis A, Kolb EA, Aplenc R, Alonzo TA, Meshinchi S, Rubnitz J, Pounds S, Lamba JK. Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials. NPJ Precis Oncol. 2024 Aug 01; 8(1):168. PMID: 39090192.
      View in: PubMed
    2. van Weelderen RE, Harrison CJ, Klein K, Jiang Y, Abrahamsson J, Alonzo T, Aplenc R, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fern?ndez Navarro JM, Gamis A, Gerbing RB, Goemans BF, de Groot-Kruseman HA, Guest E, Ha SY, Hasle H, Kelaidi C, Lapillonne H, Leverger G, Locatelli F, Miyamura T, Nor?n-Nystr?m U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan CM, Kaspers GJL. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia. Blood Adv. 2024 Jun 25; 8(12):3200-3213. PMID: 38621200.
      View in: PubMed
    3. Tarlock K, Gerbing RB, Ries RE, Smith JL, Leonti A, Huang BJ, Kirkey D, Robinson L, Peplinski JH, Lange B, Cooper TM, Gamis AS, Kolb EA, Aplenc R, Pollard JA, Alonzo TA, Meshinchi S. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Adv. 2024 05 14; 8(9):2094-2103. PMID: 38295280.
      View in: PubMed
    4. Abla O, Ries RE, Triche T, Gerbing RB, Hirsch B, Raimondi S, Cooper T, Farrar JE, Buteyn N, Harmon LM, Wen H, Deshpande AJ, Kolb EA, Gamis AS, Aplenc R, Alonzo T, Meshinchi S. Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Adv. 2024 Apr 23; 8(8):2005-2017. PMID: 38306602.
      View in: PubMed
    5. Renaud J, Goemans BF, Locatelli F, Pigazzi M, Redmond S, Kuehni CE, Destaillats A, Alonzo TA, Gerbing RB, Gamis A, Aplenc R, Renella R, Cooper T, Ceppi F. Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6?months of age: A retrospective study. Pediatr Blood Cancer. 2024 Jul; 71(7):e31006. PMID: 38616361.
      View in: PubMed
    6. van Dijk AD, Hoff FW, Qiu Y, Hubner SE, Go RL, Ruvolo VR, Leonti AR, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Horton TM, Kornblau SM. Chromatin Profiles Are Prognostic of Clinical Response to Bortezomib-Containing Chemotherapy in Pediatric Acute Myeloid Leukemia: Results from the COG AAML1031 Trial. Cancers (Basel). 2024 Apr 09; 16(8). PMID: 38672531.
      View in: PubMed
    7. Shastri VM, Chauhan L, Gbadamosi M, Alonzo TA, Wang YC, Aplenc R, Hirsch BA, Kolb EA, Gamis AS, Meshinchi S, Lamba JK. Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group. Clin Cancer Res. 2024 Jan 10. PMID: 38197878.
      View in: PubMed
    8. Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O'Dwyer K, Tallman MS, Litzow M, Atallah E, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K. Characteristics and prognostic impact of IDH mutations in AML: a?COG, SWOG, and ECOG analysis. Blood Adv. 2023 10 10; 7(19):5941-5953. PMID: 37267439.
      View in: PubMed
    9. Bertrums EJM, Smith JL, Harmon L, Ries RE, Wang YJ, Alonzo TA, Menssen AJ, Chisholm KM, Leonti AR, Tarlock K, Ostronoff F, Pogosova-Agadjanyan EL, Kaspers GJL, Hasle H, Dworzak M, Walter C, Muhlegger N, Morerio C, Pardo L, Hirsch B, Raimondi S, Cooper TM, Aplenc R, Gamis AS, Kolb EA, Farrar JE, Stirewalt D, Ma X, Shaw TI, Furlan SN, Brodersen LE, Loken MR, Van den Heuvel-Eibrink MM, Zwaan CM, Triche TJ, Goemans BF, Meshinchi S. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023 08 01; 108(8):2044-2058. PMID: 36815378.
      View in: PubMed
    10. Hoff FW, Qiu Y, Brown BD, Gerbing RB, Leonti AR, Ries RE, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, Horton TM, Kornblau SM. Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. Proteomics Clin Appl. 2023 Nov; 17(6):e2200109. PMID: 37287368.
      View in: PubMed
    11. Farrar JE, Smith JL, Othus M, Huang BJ, Wang YC, Ries R, Hylkema T, Pogosova-Agadjanyan EL, Challa S, Leonti A, Shaw TI, Triche TJ, Gamis AS, Aplenc R, Kolb EA, Ma X, Stirewalt DL, Alonzo TA, Meshinchi S. Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2023 06 01; 41(16):2949-2962. PMID: 36795987.
      View in: PubMed
    12. Chisholm KM, Smith J, Heerema-McKenney AE, Choi JK, Ries RE, Hirsch BA, Raimondi SC, Wang YC, Dang A, Alonzo TA, Sung L, Aplenc R, Gamis AS, Meshinchi S, Kahwash SB. Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2023 05; 70(5):e30251. PMID: 36789545.
      View in: PubMed
    13. Hoff FW, Van Dijk AD, Qiu Y, Hu CW, Ries RE, Ligeralde A, Jenkins GN, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Qutub AA, De Bont ESJM, Horton TM, Kornblau SM. Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study. Haematologica. 2022 10 01; 107(10):2329-2343. PMID: 35021602.
      View in: PubMed
    14. Huang BJ, Smith JL, Farrar JE, Wang YC, Umeda M, Ries RE, Leonti AR, Crowgey E, Furlan SN, Tarlock K, Armendariz M, Liu Y, Shaw TI, Wei L, Gerbing RB, Cooper TM, Gamis AS, Aplenc R, Kolb EA, Rubnitz J, Ma J, Klco JM, Ma X, Alonzo TA, Triche T, Meshinchi S. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Nat Commun. 2022 09 19; 13(1):5487. PMID: 36123353.
      View in: PubMed
    15. Tarlock K, Sulis ML, Chewning JH, Pollard JA, Cooper T, Gamis A, Shenoy S, Kutny M, Horan J, Meshinchi S, Boelens JJ, Bleakley M, Carpenter PA, Kolb EA. Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2022 09; 28(9):530-545. PMID: 35717004.
      View in: PubMed
    16. Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, De Jesus A, Wang YC, Dang A, Hirsch BA, Alonzo TA, Gamis A, Meshinchi S, Lamba JK. A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. Leukemia. 2022 08; 36(8):2022-2031. PMID: 35688939.
      View in: PubMed
    17. Pollard JA, Alonzo TA, Gerbing R, Brown P, Fox E, Choi J, Fisher B, Hirsch B, Kahwash S, Getz K, Levine J, Brodersen LE, Loken MR, Raimondi S, Tarlock K, Wood A, Sung L, Kolb EA, Gamis A, Meshinchi S, Aplenc R. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. J Clin Oncol. 2022 06 20; 40(18):2023-2035. PMID: 35349331.
      View in: PubMed
    18. Pommert L, Cooper TM, Gerbing RB, Brodersen L, Loken M, Gamis A, Aplenc R, Alonzo TA, Kolb EA. Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. Cancers (Basel). 2022 Jan 26; 14(3). PMID: 35158884.
      View in: PubMed
    19. Elsayed AH, Cao X, Mitra AK, Wu H, Raimondi S, Cogle C, Al-Mansour Z, Ribeiro RC, Gamis A, Kolb EA, Aplenc R, Alonzo TA, Meshinchi S, Rubnitz J, Pounds S, Lamba JK. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. J Clin Oncol. 2022 03 01; 40(7):772-783. PMID: 34990262.
      View in: PubMed
    20. Andolina JR, Wang YC, Ji L, Freyer DR, Levine JE, Pulsipher MA, Gamis AS, Aplenc R, Roth ME, Harrison L, Cairo MS. Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience. Bone Marrow Transplant. 2022 03; 57(3):445-452. PMID: 34992254.
      View in: PubMed
    21. Kutny MA, Alonzo TA, Abla O, Rajpurkar M, Gerbing RB, Wang YC, Hirsch BA, Raimondi S, Kahwash S, Hardy KK, Hardy S, Meshinchi S, Gamis AS, Kolb EA, Feusner JH, Gregory J. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. JAMA Oncol. 2022 Jan 01; 8(1):79-87. PMID: 34762093.
      View in: PubMed
    22. Huang BJ, Smith JL, Wang YC, Taghizadeh K, Leonti AR, Ries RE, Liu Y, Kolekar P, Tarlock K, Gerbing R, Crowgey E, Furlan SN, Shaw TI, Hagiwara K, Wei L, Cooper TM, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche T, Alonzo TA, Ma X, Meshinchi S. CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood Adv. 2021 12 14; 5(23):4963-4968. PMID: 34547772.
      View in: PubMed
    23. Hitzler J, Alonzo T, Gerbing R, Beckman A, Hirsch B, Raimondi S, Chisholm K, Viola S, Brodersen L, Loken M, Tong S, Druley T, O'Brien M, Hijiya N, Heerema-McKenney A, Wang YC, Schore R, Taub J, Gamis A, Kolb EA, Berman JN. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021 12 09; 138(23):2337-2346. PMID: 34320162.
      View in: PubMed
    24. van Dijk AD, Hoff FW, Qiu Y, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, de Bont ESJM, Kornblau SM, Horton TM. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA. Proteomics Clin Appl. 2022 03; 16(2):e2100072. PMID: 34719869.
      View in: PubMed
    25. Elgarten CW, Wood AC, Li Y, Alonzo TA, Brodersen LE, Gerbing RB, Getz KD, Huang YV, Loken M, Meshinchi S, Pollard JA, Sung L, Woods WG, Kolb EA, Gamis AS, Aplenc R. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 12; 68(12):e29281. PMID: 34596937.
      View in: PubMed
    26. Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, Brodersen LE, Pardo L, Leonti A, Smith JL, Hylkema TA, Woods WG, Cooper TM, Kolb EA, Gamis AS, Aplenc R, Alonzo TA, Meshinchi S. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. Blood. 2021 09 30; 138(13):1137-1147. PMID: 33951732.
      View in: PubMed
    27. Getz KD, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi S, Hirsch B, Loken M, Brodersen LE, Kahwash S, Choi J, Kolb EA, Gamis A, Aplenc R. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2022 01; 69(1):e29313. PMID: 34472213.
      View in: PubMed
    28. Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis AS. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2021 10 01; 39(28):3149-3160. PMID: 34048275.
      View in: PubMed
    29. Rasche M, Zimmermann M, Steidel E, Alonzo T, Aplenc R, Bourquin JP, Boztug H, Cooper T, Gamis AS, Gerbing RB, Janotova I, Klusmann JH, Lehrnbecher T, M?hlegger N, Neuhoff NV, Niktoreh N, Sramkova L, Stary J, Waack K, Walter C, Creutzig U, Dworzak M, Kaspers G, Kolb EA, Reinhardt D. Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers (Basel). 2021 May 12; 13(10). PMID: 34066095.
      View in: PubMed
    30. Narayanan P, Man TK, Gerbing RB, Ries R, Stevens AM, Wang YC, Long X, Gamis AS, Cooper T, Meshinchi S, Alonzo TA, Redell MS. Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia. Clin Transl Oncol. 2021 Oct; 23(10):2141-2154. PMID: 33948920.
      View in: PubMed
    31. Ahmed AA, Habeebu S, Farooqi MS, Gamis AS, Gonzalez E, Flatt T, Sherman A, Surrey L, Arnold MA, Conces M, Koo S, Dioufa N, Barr FG, Tsokos MG. MYOD1 as a prognostic indicator in rhabdomyosarcoma. Pediatr Blood Cancer. 2021 09; 68(9):e29085. PMID: 33913590.
      View in: PubMed
    32. Hoff FW, van Dijk AD, Qiu Y, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Bruggeman SWM, Kornblau SM, Horton TM. Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. Blood. 2021 02 25; 137(8):1050-1060. PMID: 32959058.
      View in: PubMed
    33. Chisholm KM, Heerema-McKenney AE, Choi JK, Smith J, Ries RE, Hirsch BA, Raimondi SC, Alonzo TA, Wang YC, Aplenc R, Sung L, Gamis AS, Meshinchi S, Kahwash SB. Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group. Blood Adv. 2020 12 08; 4(23):6000-6008. PMID: 33284945.
      View in: PubMed
    34. Brodersen LE, Gerbing RB, Pardo ML, Alonzo TA, Paine D, Fritschle W, Hsu FC, Pollard JA, Aplenc R, Kahwash SB, Hirsch B, Ramondi S, Wells D, Kolb EA, Gamis AS, Meshinchi S, Loken MR. Morphologic remission status is limited compared to ?N flow cytometry: a Children's Oncology Group AAML0531 report. Blood Adv. 2020 10 27; 4(20):5050-5061. PMID: 33080007.
      View in: PubMed
    35. Getz KD, Sung L, Alonzo TA, Leger KJ, Gerbing RB, Pollard JA, Cooper T, Kolb EA, Gamis AS, Ky B, Aplenc R. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2020 07 20; 38(21):2398-2406. PMID: 32343641.
      View in: PubMed
    36. Perry JM, Tao F, Roy A, Lin T, He XC, Chen S, Lu X, Nemechek J, Ruan L, Yu X, Dukes D, Moran A, Pace J, Schroeder K, Zhao M, Venkatraman A, Qian P, Li Z, Hembree M, Paulson A, He Z, Xu D, Tran TH, Deshmukh P, Nguyen CT, Kasi RM, Ryan R, Broward M, Ding S, Guest E, August K, Gamis AS, Godwin A, Sittampalam GS, Weir SJ, Li L. Overcoming Wnt-?-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nat Cell Biol. 2020 06; 22(6):689-700. PMID: 32313104.
      View in: PubMed
    37. Aplenc R, Meshinchi S, Sung L, Alonzo T, Choi J, Fisher B, Gerbing R, Hirsch B, Horton T, Kahwash S, Levine J, Loken M, Brodersen L, Pollard J, Raimondi S, Kolb EA, Gamis A. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica. 2020 07; 105(7):1879-1886. PMID: 32029509.
      View in: PubMed
    38. August KJ, Guest EM, Lewing K, Hays JA, Gamis AS. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. Pediatr Blood Cancer. 2020 03; 67(3):e28062. PMID: 31724803.
      View in: PubMed
    39. Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, Eidenschink Brodersen L, Pardo L, Cummings CL, Loeb KR, Le Q, Imren S, Leonti AR, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche TJ, Nguyen C, Meerzaman D, Loken MR, Oehler VG, Bolouri H, Meshinchi S. Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. Clin Cancer Res. 2020 02 01; 26(3):726-737. PMID: 31719049.
      View in: PubMed
    40. Orgel E, Alexander TB, Wood BL, Kahwash SB, Devidas M, Dai Y, Alonzo TA, Mullighan CG, Inaba H, Hunger SP, Raetz EA, Gamis AS, Rabin KR, Carroll AJ, Heerema NA, Berman JN, Woods WG, Loh ML, Zweidler-McKay PA, Horan JT. Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer. 2020 02 01; 126(3):593-601. PMID: 31661160.
      View in: PubMed
    41. Mast KJ, Taub JW, Alonzo TA, Gamis AS, Mosse CA, Mathew P, Berman JN, Wang YC, Jones HM, Campana D, Coustan-Smith E, Raimondi SC, Hirsch B, Hitzler JK, Head DR. Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431. Arch Pathol Lab Med. 2020 04; 144(4):466-472. PMID: 31429606.
      View in: PubMed
    42. Pardo LM, Voigt AP, Alonzo TA, Wilson ER, Gerbing RB, Paine DJ, Dai F, Menssen AJ, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Brodersen LE, Loken MR. Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Cytometry B Clin Cytom. 2020 01; 98(1):52-56. PMID: 31294507.
      View in: PubMed
    43. Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries R, Loken MR, Pardo L, Hylkema T, Joaquin J, Sarukkai L, Raimondi SC, Hirsch B, Sung L, Aplenc R, Bernstein I, Gamis AS, Meshinchi S, Pollard JA. Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. Clin Cancer Res. 2019 08 15; 25(16):5038-5048. PMID: 31182436.
      View in: PubMed
    44. Chauhan L, Shin M, Wang YC, Loken M, Pollard J, Aplenc R, Hirsch BA, Raimondi S, Ries RE, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S, Lamba JK. CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. JCO Precis Oncol. 2019; 3. PMID: 32914031.
      View in: PubMed
    45. Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, Loken MR, Pollard J, Aplenc R, Raimondi S, Hirsch BA, Bernstein ID, Gamis AS, Meshinchi S, Lamba JK. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. Blood Cancer J. 2019 05 21; 9(6):51. PMID: 31113932.
      View in: PubMed
    46. Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S. Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2019 Mar; 25(3):530. PMID: 30705421.
      View in: PubMed
    47. McNeer NA, Philip J, Geiger H, Ries RE, Lavall?e VP, Walsh M, Shah M, Arora K, Emde AK, Robine N, Alonzo TA, Kolb EA, Gamis AS, Smith M, Gerhard DS, Guidry-Auvil J, Meshinchi S, Kentsis A. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019 08; 33(8):1934-1943. PMID: 30760869.
      View in: PubMed
    48. Rajpurkar M, Alonzo TA, Wang YC, Gerbing RB, Gamis AS, Feusner JH, Gregory J, Kutny MA. Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631. J Pediatr Hematol Oncol. 2019 01; 41(1):51-55. PMID: 30095694.
      View in: PubMed
    49. Getz KD, Sung L, Ky B, Gerbing RB, Leger KJ, Leahy AB, Sack L, Woods WG, Alonzo T, Gamis A, Aplenc R. Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. J Clin Oncol. 2019 01 01; 37(1):12-21. PMID: 30379624.
      View in: PubMed
    50. Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S. Erratum: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018 Apr 10; 24(4):526. PMID: 29634680.
      View in: PubMed
    51. Lamba JK, Voigt AP, Chauhan L, Shin M, Aplenc R, Eidenschink Brodersen L, Gamis AS, Meshinchi S, Loken MR. CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. Leuk Lymphoma. 2018 09; 59(9):2250-2253. PMID: 29320902.
      View in: PubMed
    52. Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018 01; 24(1):103-112. PMID: 29227476.
      View in: PubMed
    53. Lim EL, Trinh DL, Ries RE, Wang J, Gerbing RB, Ma Y, Topham J, Hughes M, Pleasance E, Mungall AJ, Moore R, Zhao Y, Aplenc R, Sung L, Kolb EA, Gamis A, Smith M, Gerhard DS, Alonzo TA, Meshinchi S, Marra MA. MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2017 Dec 10; 35(35):3964-3977. PMID: 29068783.
      View in: PubMed
    54. Voigt AP, Brodersen LE, Alonzo TA, Gerbing RB, Menssen AJ, Wilson ER, Kahwash S, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Loken MR. Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531. Haematologica. 2017 12; 102(12):2058-2068. PMID: 28883080.
      View in: PubMed
    55. Kutny MA, Alonzo TA, Gerbing RB, Wang YC, Raimondi SC, Hirsch BA, Fu CH, Meshinchi S, Gamis AS, Feusner JH, Gregory JJ. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. J Clin Oncol. 2017 Sep 10; 35(26):3021-3029. PMID: 28767288.
      View in: PubMed
    56. Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. Blood. 2017 08 17; 130(7):943-945. PMID: 28674028.
      View in: PubMed
    57. Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2017 Aug 10; 35(23):2674-2682. PMID: 28644774.
      View in: PubMed
    58. Miller TP, Li Y, Kavcic M, Getz KD, Huang YV, Sung L, Alonzo TA, Gerbing R, Daves MH, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2017 09; 102(9):e340-e343. PMID: 28642300.
      View in: PubMed
    59. Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, Meshinchi S, Gamis AS. Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 Dec; 64(12). PMID: 28453910.
      View in: PubMed
    60. Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Wang YC, Gerbing RB, Sung L, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. 2017 06 08; 129(23):3051-3058. PMID: 28411282.
      View in: PubMed
    61. Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 2017 06 22; 129(25):3304-3313. PMID: 28389462.
      View in: PubMed
    62. Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash SB, McKenney A, Kolb EA, Gamis AS, Meshinchi S. Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2017 Jul 15; 23(14):3649-3656. PMID: 28108543.
      View in: PubMed
    63. Schultz KA, Chen L, Kunin-Batson A, Chen Z, Woods WG, Gamis A, Kawashima T, Oeffinger KC, Nicholson HS, Neglia JP. Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children's Oncology Group. J Pediatr Hematol Oncol. 2017 01; 39(1):20-25. PMID: 27906794.
      View in: PubMed
    64. Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Hematol Oncol. 2016 11 30; 9(1):133. PMID: 27903291.
      View in: PubMed
    65. Gerbing RB, Alonzo TA, Sung L, Gamis AS, Meshinchi S, Plon SE, Bertuch AA, Gramatges MM. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. J Clin Oncol. 2016 11 01; 34(31):3766-3772. PMID: 27354474.
      View in: PubMed
    66. Brown FC, Cifani P, Drill E, He J, Still E, Zhong S, Balasubramanian S, Pavlick D, Yilmazel B, Knapp KM, Alonzo TA, Meshinchi S, Stone RM, Kornblau SM, Marcucci G, Gamis AS, Byrd JC, Gonen M, Levine RL, Kentsis A. Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. Br J Haematol. 2017 Jan; 176(1):86-91. PMID: 27766616.
      View in: PubMed
    67. Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, Meshinchi S. miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. Pediatr Blood Cancer. 2016 12; 63(12):2096-2103. PMID: 27511899.
      View in: PubMed
    68. Vujkovic M, Aplenc R, Alonzo TA, Gamis AS, Li Y. Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group. Front Genet. 2016; 7:139. PMID: 27547214.
      View in: PubMed
    69. Getz KD, Miller TP, Seif AE, Li Y, Huang YS, Alonzo T, Gerbing R, Sung L, Hall M, Bagatell R, Gamis A, Fisher BT, Aplenc R. Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. Cancer Med. 2016 09; 5(9):2412-6. PMID: 27474232.
      View in: PubMed
    70. Sung L, Aplenc R, Alonzo TA, Gerbing RB, Wang YC, Meshinchi S, Gamis AS. Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group. Int J Cancer. 2016 Nov 01; 139(9):1930-5. PMID: 27312107.
      View in: PubMed
    71. Maxson JE, Ries RE, Wang YC, Gerbing RB, Kolb EA, Thompson SL, Guidry Auvil JM, Marra MA, Ma Y, Zong Z, Mungall AJ, Moore R, Long W, Gesuwan P, Davidsen TM, Hermida LC, Hughes SB, Farrar JE, Radich JP, Smith MA, Gerhard DS, Gamis AS, Alonzo TA, Meshinchi S. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood. 2016 06 16; 127(24):3094-8. PMID: 27143256.
      View in: PubMed
    72. Eidenschink Brodersen L, Alonzo TA, Menssen AJ, Gerbing RB, Pardo L, Voigt AP, Kahwash SB, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Loken MR. A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group. Leukemia. 2016 10; 30(10):2077-2080. PMID: 27133823.
      View in: PubMed
    73. Farrar JE, Schuback HL, Ries RE, Wai D, Hampton OA, Trevino LR, Alonzo TA, Guidry Auvil JM, Davidsen TM, Gesuwan P, Hermida L, Muzny DM, Dewal N, Rustagi N, Lewis LR, Gamis AS, Wheeler DA, Smith MA, Gerhard DS, Meshinchi S. Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Res. 2016 04 15; 76(8):2197-205. PMID: 26941285.
      View in: PubMed
    74. Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 05 01; 34(13):1537-43. PMID: 26884558.
      View in: PubMed
    75. Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2016 Mar 01; 34(7):747-55. PMID: 26786921.
      View in: PubMed
    76. Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2016 07; 57(7):1567-74. PMID: 26727639.
      View in: PubMed
    77. Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 Apr 15; 22(8):1951-7. PMID: 26644412.
      View in: PubMed
    78. Li Y, Hall M, Fisher BT, Seif AE, Huang YS, Bagatell R, Getz KD, Alonzo TA, Gerbing RB, Sung L, Adamson PC, Gamis A, Aplenc R. Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. PLoS One. 2015; 10(11):e0143480. PMID: 26606521.
      View in: PubMed
    79. Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Hematol Oncol. 2015 10 20; 8:115. PMID: 26487643.
      View in: PubMed
    80. Stevens AM, Ruiz MJ, Gerbing RB, Alonzo TA, Gamis AS, Redell MS. Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2015 Dec; 100(12):e496-500. PMID: 26294728.
      View in: PubMed
    81. Kutny MA, Alonzo TA, Gamazon ER, Gerbing RB, Geraghty D, Lange B, Heerema NA, Sung L, Aplenc R, Franklin J, Raimondi SC, Hirsch BA, Konkashbaev A, Cox NJ, Onel K, Gamis AS, Meshinchi S. Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group. Leukemia. 2015 Dec; 29(12):2424-6. PMID: 26126966.
      View in: PubMed
    82. Vujkovic M, Attiyeh EF, Ries RE, Horn M, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Gerbing RB, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. Cancer Genet. 2015 Jul-Aug; 208(7-8):408-13. PMID: 26163103.
      View in: PubMed
    83. Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R. Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Oct; 62(10):1775-81. PMID: 25946708.
      View in: PubMed
    84. Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2015 Jul 15; 21(14):3187-95. PMID: 25825478.
      View in: PubMed
    85. Gamis AS. Earlier initiation of antibiotic therapy: Does prophylaxis offer greater benefit in AML? Pediatr Blood Cancer. 2015 Jul; 62(7):1121-2. PMID: 25808288.
      View in: PubMed
    86. Miller TP, Troxel AB, Li Y, Huang YS, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R. Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Jul; 62(7):1184-9. PMID: 25760019.
      View in: PubMed
    87. Linabery AM, Li W, Roesler MA, Spector LG, Gamis AS, Olshan AF, Heerema NA, Ross JA. Immune-related conditions and acute leukemia in children with Down syndrome: a Children's Oncology Group report. Cancer Epidemiol Biomarkers Prev. 2015 Feb; 24(2):454-8. PMID: 25499068.
      View in: PubMed
    88. Trippett TM, Schwartz CL, Guillerman RP, Gamis AS, Gardner S, Hogan S, London WB, Chen L, de Alarcon P. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Pediatr Blood Cancer. 2015 Jan; 62(1):60-4. PMID: 25308760.
      View in: PubMed
    89. Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children?s Oncology Group trial AAML0531. J Clin Oncol. 2014 Sep 20; 32(27):3021-32. PMID: 25092781.
      View in: PubMed
    90. Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014 Oct 09; 124(15):2400-7. PMID: 25145343.
      View in: PubMed
    91. Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Oct; 61(10):1754-60. PMID: 24976003.
      View in: PubMed
    92. Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014 Aug 15; 120(16):2482-9. PMID: 24771494.
      View in: PubMed
    93. Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, Meshinchi S. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. Br J Haematol. 2014 Jul; 166(2):254-259. PMID: 24661089.
      View in: PubMed
    94. Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2014 Dec; 55(12):2817-21. PMID: 24559289.
      View in: PubMed
    95. McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014 Feb 01; 20(3):754-63. PMID: 24218510.
      View in: PubMed
    96. Lee GE, Sung L, Fisher BT, Sullivan KE, McWilliams T, Tobias JW, Meshinchi S, Alonzo TA, Gamis A, Aplenc R. Gene expression profiling to predict viridans group streptococcal and invasive fungal infection in pediatric acute myeloid leukemia: a brief report from the Children's Oncology Group. Acta Haematol. 2014; 131(3):167-9. PMID: 24217778.
      View in: PubMed
    97. Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S. BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Apr; 61(4):647-52. PMID: 24127439.
      View in: PubMed
    98. Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, Lange BJ, Meshinchi S, Woods WG, Perentesis J, Horan J. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer. 2013 Dec 01; 119(23):4162-9. PMID: 24104395.
      View in: PubMed
    99. Johnston DL, Alonzo TA, Gerbing RB, Hirsch B, Heerema NA, Ravindranath Y, Woods WG, Lange BJ, Gamis AS, Raimondi SC. Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2013 Dec; 60(12):2073-8. PMID: 24039149.
      View in: PubMed
    100. Malinge S, Chlon T, Dor? LC, Ketterling RP, Tallman MS, Paietta E, Gamis AS, Taub JW, Chou ST, Weiss MJ, Crispino JD, Figueroa ME. Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood. 2013 Oct 03; 122(14):e33-43. PMID: 23980066.
      View in: PubMed
    101. Ho PA, Alonzo TA, Gerbing RB, Kuhn J, Pollard JA, Hirsch B, Raimondi SC, Gamis AS, Meshinchi S. The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Jan; 61(1):81-8. PMID: 23956224.
      View in: PubMed
    102. Ho PA, Alonzo TA, Gerbing RB, Pollard JA, Hirsch B, Raimondi SC, Cooper T, Gamis AS, Meshinchi S. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. Br J Haematol. 2013 Sep; 162(5):670-7. PMID: 23826732.
      View in: PubMed
    103. Walter RB, Laszlo GS, Alonzo TA, Gerbing RB, Levy S, Fitzgibbon MP, Gudgeon CJ, Ries RE, Harrington KH, Raimondi SC, Hirsch BA, Gamis AS, W McIntosh M, Meshinchi S. Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. Am J Hematol. 2013 Aug; 88(8):694-702. PMID: 23686445.
      View in: PubMed
    104. Lacayo NJ, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC, Cesano A, Gerbing R, Ravindranath Y, Dahl GV, Gamis A, Meshinchi S. Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group. Br J Haematol. 2013 Jul; 162(2):250-62. PMID: 23682827.
      View in: PubMed
    105. Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group. Blood. 2013 May 02; 121(18):3573-7. PMID: 23471307.
      View in: PubMed
    106. Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, Meshinchi S, Lamba JK. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. Clin Cancer Res. 2013 Mar 15; 19(6):1620-7. PMID: 23444229.
      View in: PubMed
    107. McCune JS, Baker KS, Blough DK, Gamis A, Bemer MJ, Kelton-Rehkopf MC, Winter L, Barrett JS. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol. 2013 Mar; 53(3):264-75. PMID: 23444282.
      View in: PubMed
    108. Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, Gamis AS, Perentesis J, Whitlock JA. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group. Pediatr Blood Cancer. 2013 Jul; 60(7):1141-7. PMID: 23335239.
      View in: PubMed
    109. Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S. Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia. Pediatr Blood Cancer. 2013 Jun; 60(6):964-71. PMID: 23255301.
      View in: PubMed
    110. Taylor DS, Dharmar M, Urquhart-Scott E, Ryan R, Pulsipher MA, Gamis A, Schultz K, Marcin JP. Relationship between pediatric blood and marrow transplant center volume and day +100 mortality: Pediatric Blood and Marrow Transplant Consortium experience. Bone Marrow Transplant. 2013 Apr; 48(4):514-22. PMID: 23147599.
      View in: PubMed
    111. Gamis AS, Smith FO. Transient myeloproliferative disorder in children with Down syndrome: clarity to this enigmatic disorder. Br J Haematol. 2012 Nov; 159(3):277-87. PMID: 22966823.
      View in: PubMed
    112. Wen Q, Goldenson B, Silver SJ, Schenone M, Dancik V, Huang Z, Wang LZ, Lewis TA, An WF, Li X, Bray MA, Thiollier C, Diebold L, Gilles L, Vokes MS, Moore CB, Bliss-Moreau M, Verplank L, Tolliday NJ, Mishra R, Vemula S, Shi J, Wei L, Kapur R, Lopez CK, Gerby B, Ballerini P, Pflumio F, Gilliland DG, Goldberg L, Birger Y, Izraeli S, Gamis AS, Smith FO, Woods WG, Taub J, Scherer CA, Bradner JE, Goh BC, Mercher T, Carpenter AE, Gould RJ, Clemons PA, Carr SA, Root DE, Schreiber SL, Stern AM, Crispino JD. Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell. 2012 Aug 03; 150(3):575-89. PMID: 22863010.
      View in: PubMed
    113. Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica. 2012 Nov; 97(11):1770-3. PMID: 22801969.
      View in: PubMed
    114. Gudgeon CJ, Harrington KH, Laszlo GS, Alonzo TA, Gerbing RB, Gamis AS, Raimondi SC, Hirsch BA, Meshinchi S, Walter RB. High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2013 Jan; 54(1):202-4. PMID: 22680764.
      View in: PubMed
    115. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012 Aug 23; 120(8):1581-8. PMID: 22649108.
      View in: PubMed
    116. Aplenc R, Fisher BT, Huang YS, Li Y, Alonzo TA, Gerbing RB, Hall M, Bertoch D, Keren R, Seif AE, Sung L, Adamson PC, Gamis A. Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:37-43. PMID: 22552978.
      View in: PubMed
    117. Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci RJ, Woods WG, Gamis AS. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer. 2012 Oct 01; 118(19):4806-14. PMID: 22392565.
      View in: PubMed
    118. Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB, Gamis A, Meshinchi S. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood. 2012 Apr 19; 119(16):3705-11. PMID: 22378848.
      View in: PubMed
    119. Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, Woods WG, Meshinchi S. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Oct; 59(4):662-7. PMID: 22378655.
      View in: PubMed
    120. Sung L, Buxton A, Gamis A, Woods WG, Alonzo TA. Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2012 Jan; 34(1):e30-5. PMID: 22052170.
      View in: PubMed
    121. Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Blood. 2011 Oct 27; 118(17):4561-6. PMID: 21873548.
      View in: PubMed
    122. Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, Massey G, Perentesis J, Ravindranath Y, Taub J, Smith FO. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 2011 Dec 22; 118(26):6752-9; quiz 6996. PMID: 21849481.
      View in: PubMed
    123. Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis A. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2012 Feb 01; 118(3):761-9. PMID: 21766293.
      View in: PubMed
    124. Mathew P, Gerbing R, Alonzo TA, Wallas T, Gong JZ, Jasty R, Jorstad DT, Raimondi SC, Chavez CM, Eisenberg NL, Hirsch B, Gamis A, Smith FO, Arceci RJ. A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121). Pediatr Blood Cancer. 2011 Dec 15; 57(7):1230-2. PMID: 21681928.
      View in: PubMed
    125. Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, Meshinchi S. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Aug; 57(2):204-9. PMID: 21504050.
      View in: PubMed
    126. Berman JN, Gerbing RB, Alonzo TA, Ho PA, Miller K, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Gamis A, Meshinchi S. Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group. Leukemia. 2011 Jun; 25(6):1039-42. PMID: 21358716.
      View in: PubMed
    127. Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch BA, Franklin JL, Lange B, Gamis AS, Alonzo TA, Meshinchi S. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol. 2011 Feb 20; 29(6):704-11. PMID: 21189390.
      View in: PubMed
    128. Radhi M, Meshinchi S, Gamis A. Prognostic factors in pediatric acute myeloid leukemia. Curr Hematol Malig Rep. 2010 Oct; 5(4):200-6. PMID: 20652454.
      View in: PubMed
    129. Kraft SM, Singh V, Sykes KJ, Gamis A, Manalang MA, Wei JL. Differentiating between congenital rhabdomyosarcoma versus fibromatosis of the pediatric tongue. Int J Pediatr Otorhinolaryngol. 2010 Jul; 74(7):781-5. PMID: 20435354.
      View in: PubMed
    130. Aguayo P, Ho B, Fraser JD, Gamis A, St Peter SD, Snyder CL. Bowel obstruction after treatment of intra-abdominal tumors. Eur J Pediatr Surg. 2010 Jul; 20(4):234-6. PMID: 20496318.
      View in: PubMed
    131. Pulsipher MA, Hunger SP, Gamis AS, Wall DA, Grupp SA. Allogeneic marrow transplantation in children with acute leukemia: careful comparison with chemotherapy alternatives required. Leukemia. 2010 Jun; 24(6):1212-6. PMID: 20428198.
      View in: PubMed
    132. Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA, Loken MR, Meshinchi S. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol. 2010 Jun 10; 28(17):2831-8. PMID: 20421533.
      View in: PubMed
    133. Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Reaman GH, Baker LH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia. 2010 May; 24(5):909-13. PMID: 20376086.
      View in: PubMed
    134. Flatt T, Lewing K, Gonzalez C, Anthony K, Ryan R, Jones R, Gamis A, Dalal J. Successful mobilization with AMD3100 and filgrastim with engraftment of autologous peripheral blood stem cells in a heavily pretreated pediatric patient with recurrent Burkitt lymphoma. Pediatr Hematol Oncol. 2010 Mar; 27(2):138-49. PMID: 20201695.
      View in: PubMed
    135. Bhat R, Malinge S, Gamis AS, Sorrell AD, Hilden JM, Ketterling RP, Paietta E, Tallman MS, Crispino JD. Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia. Leukemia. 2009 Nov; 23(11):2159-60. PMID: 19657363.
      View in: PubMed
    136. Lehrnbecher T, Ethier MC, Zaoutis T, Creutzig U, Gamis A, Reinhardt D, Aplenc R, Sung L. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol. 2009 Oct; 147(1):125-8. PMID: 19663826.
      View in: PubMed
    137. Sung L, Gamis A, Alonzo TA, Buxton A, Britton K, Deswarte-Wallace J, Woods WG. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009 Mar 01; 115(5):1100-8. PMID: 19156894.
      View in: PubMed
    138. Sung L, Alonzo TA, Gerbing RB, Aplenc R, Lange BJ, Woods WG, Feusner J, Franklin J, Patterson MJ, Gamis AS. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008 Dec; 51(6):784-6. PMID: 18680152.
      View in: PubMed
    139. Sung L, Alibhai SM, Beyene J, Gamis A, Almeida R, Smith S, Aplenc R. Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: a meta-analysis of randomized trials. Leukemia. 2009 Apr; 23(4):811-3. PMID: 18987652.
      View in: PubMed
    140. Linabery AM, Blair CK, Gamis AS, Olshan AF, Heerema NA, Ross JA. Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008 Oct; 17(10):2572-7. PMID: 18829445.
      View in: PubMed
    141. Blair CK, Roesler M, Xie Y, Gamis AS, Olshan AF, Heerema NA, Robison LL, Ross JA. Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study. Paediatr Perinat Epidemiol. 2008 May; 22(3):288-95. PMID: 18426524.
      View in: PubMed
    142. Norton A, Fisher C, Liu H, Wen Q, Mundschau G, Fuster JL, Hasle H, Zeller B, Webb DK, O'Marcaigh A, Sorrell A, Hilden J, Gamis A, Crispino JD, Vyas P. Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. Blood. 2007 Aug 01; 110(3):1077-9. PMID: 17644747.
      View in: PubMed
    143. Linabery AM, Olshan AF, Gamis AS, Smith FO, Heerema NA, Blair CK, Ross JA. Exposure to medical test irradiation and acute leukemia among children with Down syndrome: a report from the Children's Oncology Group. Pediatrics. 2006 Nov; 118(5):e1499-508. PMID: 17030598.
      View in: PubMed
    144. Gamis AS. Surveys: a tool to provoke thought and identify areas of need. Pediatr Blood Cancer. 2005 Mar; 44(3):205-6. PMID: 15452913.
      View in: PubMed
    145. Gamis AS. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review. Pediatr Blood Cancer. 2005 Jan; 44(1):13-20. PMID: 15534881.
      View in: PubMed
    146. Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis. 2003 Nov-Dec; 31(3):351-6. PMID: 14636651.
      View in: PubMed
    147. Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol. 2003 Aug 01; 21(15):2940-7. PMID: 12885813.
      View in: PubMed
    148. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol. 2003 Sep 15; 21(18):3415-22. PMID: 12885836.
      View in: PubMed
    149. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003 Jun 01; 101(11):4298-300. PMID: 12560215.
      View in: PubMed
    150. Gamis AS, Hilden JM. Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia? J Pediatr Hematol Oncol. 2002 Jan; 24(1):2-5. PMID: 11902733.
      View in: PubMed
    151. Sandler ES, Hagg R, Coppes MJ, Mustafa MM, Gamis A, Kamani N, Wall D. Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium. Med Pediatr Oncol. 2000 Oct; 35(4):403-9. PMID: 11025470.
      View in: PubMed
    152. Gamis AS, Howells WB, DeSwarte-Wallace J, Feusner JH, Buckley JD, Woods WG. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891. J Clin Oncol. 2000 May; 18(9):1845-55. PMID: 10784625.
      View in: PubMed
    153. Rothberg PG, Gamis AS, Baker D. Use of DNA polymorphisms to monitor engraftment after allogeneic bone marrow transplantation. Clin Lab Med. 1997 Mar; 17(1):109-18. PMID: 9138894.
      View in: PubMed
    154. McDermott M, Gamis AS, el-Mofty S, Dehner LP. Adenocarcinoma of minor salivary gland origin with skeletal metastasis in a child. Pediatr Pathol Lab Med. 1996 Jan-Feb; 16(1):89-98. PMID: 8963634.
      View in: PubMed
    155. Barker GJ, Call SK, Gamis AS. Oral care with vancomycin paste for reduction in incidence of alpha-hemolytic streptococcal sepsis. J Pediatr Hematol Oncol. 1995 May; 17(2):151-5. PMID: 7749765.
      View in: PubMed
    156. Gamis AS, Haake R, McGlave P, Ramsay NK. Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children. J Clin Oncol. 1993 May; 11(5):834-8. PMID: 8487047.
      View in: PubMed
    157. Gamis AS, Gudnason T, Giebink GS, Ramsay NK. Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev Infect Dis. 1991 Nov-Dec; 13(6):1077-88. PMID: 1775841.
      View in: PubMed
    158. Gamis AS, Nesbit ME. Neuropsychologic (cognitive) disabilities in long-term survivors of childhood cancer. Pediatrician. 1991; 18(1):11-9. PMID: 1701051.
      View in: PubMed
    159. Gamis AS, Egelhoff J, Roloson G, Young J, Woods GM, Newman R, Freeman AI. Diffuse bony metastases at presentation in a child with glioblastoma multiforme. A case report. Cancer. 1990 Jul 01; 66(1):180-4. PMID: 2162242.
      View in: PubMed
    160. Friesen CA, Gamis AS, Riddell LD, Roberts CC, Jackson MA. Bilirubinuria: an early indicator of gallbladder hydrops associated with Kawasaki disease. J Pediatr Gastroenterol Nutr. 1989 Apr; 8(3):384-6. PMID: 2709270.
      View in: PubMed
    161. Gamis AS, Knapp JF, Glenski JA. Nitrous oxide analgesia in a pediatric emergency department. Ann Emerg Med. 1989 Feb; 18(2):177-81. PMID: 2916783.
      View in: PubMed
    162. Gamis AS, Wasserman GS. Acute acetone intoxication in a pediatric patient. Pediatr Emerg Care. 1988 Mar; 4(1):24-6. PMID: 3362729.
      View in: PubMed
    Gamis's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (446) concept(s)
    _
    Co-Authors Expand Description
    See all (7) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department